Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: DENMARK

Sector: Biotechnology

Ascendis Pharma A/S manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes.
Website: ascendispharma.com


  • Good financial results growth rate 10.7% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (83.2%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 0.7% (LTM)
  • Share price is 150.4% higher than minimum and 12.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $4.4 mln (-0.034% of cap.)

Key Financials (Download financials)

Ticker: ASND
Share price, USD:  (+2.6%)215.6
year average price 210.41  


year start price 170.80 2025-06-13

min close price 163.32 2025-07-29

max close price 247.58 2026-05-22

current price 215.60 2026-06-12
Common stocks: 54 131 524

Dividend Yield:  0.0%
EV / Sales: 30.0x
Margin (EBITDA LTM / Revenue): -83.4%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 11 356
Net Debt ($m): 192
EV (Enterprise Value): 11 548
EBITDA LTM (млн $): -321
Price to Book: -56.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-14zacks.com

Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?

2026-01-12seekingalpha.com

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-05seekingalpha.com

Ascendis: Q3 Results Validate The TransCon Platform

2025-11-25reuters.com

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

2025-11-12seekingalpha.com

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

2025-08-09seekingalpha.com

Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

2025-05-01seekingalpha.com

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

2025-04-14seekingalpha.com

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

2025-04-14accessnewswire.com

Ascendant Resources Notifies Shareholders Of Upcoming Special Meeting

2025-02-12seekingalpha.com

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND
reportedCurrency EUR EUR EUR EUR EUR EUR EUR EUR EUR USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-07 2024-09-30 2024-05-02 2024-02-07 2023-09-30 2023-06-30 2023-04-27 2022-09-30
acceptedDate 2025-11-12 16:15:33 2025-08-07 16:16:37 2025-02-12 16:15:38 2024-09-30 00:00:00 2024-05-02 16:22:05 2024-02-07 16:05:50 2024-02-07 16:15:52 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-04-27 16:01:27 2023-02-16 16:31:10 2022-09-30 00:00:00 2022-03-02 16:20:10 2021-03-10 16:50:24
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 214M 158M 364M 58M 36M 96M 267M 48M 47M 34M 51M 15M 8M 7M
costOfRevenue 22M 31M 44M 11M 11M 8M 44M 7M 13M 5M 12M 2M 4M 0
grossProfit 191M 127M 319M 47M 25M 88M 222M 41M 34M 29M 39M 14M 4M 7M
grossProfitRatio 0.895 0.801 0.806 0.682 0.921 0.846 0.727 0.862 0.889
researchAndDevelopmentExpenses 67M 72M 307M 74M 83M 71M 413M 111M 105M 106M 380M 97M 296M 261M
generalAndAdministrativeExpenses 0 106M 285M 68M 72M 0 259M 0 0 0 216M 0 0 0
sellingAndMarketingExpenses 0 0 0 0 2M 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 113M 106M 285M 68M 74M 67M 259M 64M 70M 67M 216M 61M 160M 77M
otherExpenses 0 2M 7M 2M 0 0 6M 0 0 0 5M 0 0 0
operatingExpenses 180M 180M 598M 143M 158M 137M 678M 175M 175M 173M 601M 158M 456M 338M
costAndExpenses 203M 211M 642M 155M 169M 145M 722M 182M 188M 177M 613M 160M 460M 338M
interestIncome 0 55M 14M 28M 49M 4M 17M 4M 36M 45M 7M 20M 692 000 2M
interestExpense 0 33M 66M 25M 20M 77M 44M 25M 9M 10M 31M 41M 4M 2M
depreciationAndAmortization 4M 4M 18M 2M 2M 5M 19M 5M 5M 48M 18M 21M 15M 9M
ebitda -53M 2M -290M -71M -88M -47M -411M -132M -108M -95M -529M -123M -365M -408M
ebitdaratio -0.25 0.015 -1.23 -2.431 -0.489 -2.755 -2.276 -2.835 -8.068
operatingIncome 11M -53M -279M -97M -133M -49M -456M -134M -141M -144M -562M -145M -452M -331M
operatingIncomeRatio 0.051 -0.335 -1.673 -3.702 -0.512 -2.798 -2.972 -4.278 -9.451
totalOtherIncomeExpensesNet -68M 18M -94M -1M 24M -79M -19M -7M -7M 34M -16M -25M 68M -89M
incomeBeforeTax -57M -35M -373M -98M -109M -129M -474M -162M -122M -110M -578M -169M -384M -419M
incomeBeforeTaxRatio -0.269 -0.222 -1.698 -3.032 -1.34 -3.364 -2.571 -3.263 -11.061
incomeTaxExpense 4M 4M 5M 1M 229 000 3M 7M 645 000 -429 000 1M 5M -167 000 -367 000 -219 000
netIncome -61M -39M -378M -99M -109M -131M -481M -162M -121M -111M -583M -169M -384M -419M
netIncomeRatio -0.285 -0.246 -1.715 -3.039 -1.366 -3.377 -2.562 -3.302 -11.05
eps -1 -0.64 -6.53 0 -1.91 -2.3 -8.55 -2.88 -2.16 -1.98 -10.4 -3.03 -7 -8.28
epsdiluted -1 -0.82 0 -1.91 -2.3 -2.88 -2.16 -1.98 -3.03
weightedAverageShsOut 61M 60M 58M 0 57M 57M 56M 56M 56M 56M 56M 56M 55M 51M
weightedAverageShsOutDil 61M 64M 58M 0 57M 57M 56M 56M 56M 56M 56M 56M 55M 51M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-12 2024-02-07 2023-02-16 2022-03-02 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -51M -27M -23M -3M -106 000
ebit -308M -430M -547M -380M -417M
nonOperatingIncomeExcludingInterest 29M -25M -15M -72M 87M
netIncomeFromContinuingOperations -378M -481M -583M -384M -419M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -378M -481M -583M -384M -419M
epsDiluted -6.53 -8.55 -10.4 -7 -8.28

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND
reportedCurrency EUR EUR EUR EUR EUR EUR EUR EUR EUR USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-07 2024-09-30 2024-05-02 2024-02-07 2023-09-30 2023-06-30 2023-04-27 2022-09-30
acceptedDate 2025-11-12 16:15:33 2025-08-07 16:16:37 2025-02-12 16:15:38 2024-09-30 00:00:00 2024-05-02 16:22:05 2024-02-07 16:05:50 2024-02-07 16:15:52 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-04-27 16:01:27 2023-02-16 16:31:10 2022-09-30 00:00:00 2022-03-02 16:20:10 2021-03-10 16:50:24
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 539M 494M 560M 626M 259M 320M 392M 441M 394M 501M 445M 608M 446M 585M
shortTermInvestments 0 0 0 0 0 0 7M 14M 37M 84M 291M 311M 236M 134M
cashAndShortTermInvestments 539M 494M 560M 626M 259M 320M 399M 455M 431M 586M 735M 920M 682M 719M
netReceivables 135M 110M 166M 50M 81M 41M 36M 50M 36M 35M 12M 22M 2M 387 000
inventory 302M 303M 296M 265M 251M 233M 209M 189M 168M 151M 131M 104M 75M 0
otherCurrentAssets 42M 45M 11M 32M 37M 70M 20M 38M 43M 39M 14M 35M 21M 7M
totalCurrentAssets 1 018M 953M 1 061M 974M 627M 664M 703M 733M 678M 810M 923M 1 080M 806M 740M
propertyPlantEquipmentNet 102M 94M 99M 98M 104M 107M 111M 126M 125M 128M 129M 139M 126M 108M
goodwill 0 0 3M 0 0 0 3M 0 0 0 3M 0 3M 3M
intangibleAssets 4M 4M 533 000 0 4M 4M 924 000 4M 0 0 1M 0 2M 2M
goodwillAndIntangibleAssets 4M 4M 4M 4M 4M 4M 4M 4M 5M 5M 5M 5M 5M 6M
longTermInvestments 28M 35M 14M 16M 23M 25M 6M 8M 14M 22M 30M 47M 146M 124M
taxAssets 0 0 0 0 -2M 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 3M 2M 2M 63 639 2M 2M 2M 2M 2M 2M 2M 2M 1M
totalNonCurrentAssets 137M 135M 119M 120M 131M 138M 123M 140M 146M 156M 166M 194M 279M 240M
otherAssets 0 0 0 0 -77 016 0 0 0 0 0 0 0 0 0
totalAssets 1 155M 1 088M 1 179M 1 094M 758M 803M 826M 873M 824M 966M 1 090M 1 273M 1 085M 980M
accountPayables 79M 94M 96M 75M 100M 95M 95M 122M 122M 131M 101M 86M 59M 22M
shortTermDebt 482M 462M 492M 450M 454M 439M 421M 26M 27M 25M 413M 20M 7M 0
taxPayables 0 0 1M 1M 1M 3M 2M 6M 6M 7M 5M 126 000 198 000 301 000
deferredRevenue 4M 2M 936 000 2M 0 1M 1M 4M 4M 10M 0 3M 3M 363 000
otherCurrentLiabilities 421M 377M 318M 311M 294M 262M 203M 61M 39M 32M 183M 34M 24M 23M
totalCurrentLiabilities 986M 935M 908M 838M 848M 799M 737M 213M 192M 198M 717M 143M 100M 53M
longTermDebt 331M 330M 365M 339M 219M 230M 223M 640M 479M 480M 95M 533M 98M 0
deferredRevenueNonCurrent 692 000 692 000 5M 5M 5M 5M 6M 949 000 949 000 4M 14M 13M 3M 0
deferredTaxLiabilitiesNonCurrent 10M 10M 7M 9M 8M 7M 6M 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 -85M 93M 86M 117M -95M 570M -98M 3M
totalNonCurrentLiabilities 342M 340M 377M 353M 232M 242M 235M 734M 567M 601M 110M 679M 101M 88M
otherLiabilities 0 0 0 0 -498 482 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 99M 105M 0 0 109M 0 105M 92M
totalLiabilities 1 329M 1 275M 1 285M 1 191M 1 079M 1 041M 971M 947M 759M 799M 826M 822M 201M 141M
preferredStock 0 0 0 0 0 239M 0 76M 0 0 0 0 0 0
commonStock 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 7M
retainedEarnings -2 705M -2 666M -2 560M -2 547M -2 474M -2 393M -2 277M -2 208M 0 0 -1 860M 0 -1 236M -1 030M
accumulatedOtherComprehensiveIncomeLoss -1M 309 000 2M 953 000 -329M -246M 720 999 -81M 57M 160M 3M 444M 4M 133M
othertotalStockholdersEquity 2 524M 2 470M 2 441M 2 474M 2 393M 2 132M 0 0 0
totalStockholdersEquity -174M -188M -106M -97M -321M -238M -146M -73M 65M 167M 263M 452M 884M 839M
totalEquity -174M -188M -106M -97M -321M -238M -146M -73M 65M 167M 263M 452M 884M 839M
totalLiabilitiesAndStockholdersEquity 1 155M 1 088M 1 094M 758M 803M 873M 824M 966M 1 273M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 155M 1 088M 1 179M 1 094M 758M 803M 826M 873M 824M 966M 1 090M 1 273M 1 085M 980M
totalInvestments 28M 35M 14M 16M 23M 25M 13M 22M 51M 106M 321M 359M 382M 259M
totalDebt 814M 793M 857M 789M 673M 669M 743M 666M 506M 505M 618M 553M 210M 92M
netDebt 275M 298M 297M 163M 414M 349M 351M 225M 112M 4M 173M -55M -236M -493M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-12 2024-02-07 2023-02-16 2022-03-02 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 166M 36M 12M 2M 387 000
otherReceivables 0 0 0 0 0
prepaids 28M 39M 32M 25M 14M
totalPayables 98M 97M 107M 60M 22M
otherPayables 1M 2M 5M 198 000 301 000
accruedExpenses 0 0 0 0 0
capitalLeaseObligationsCurrent 0 14M 14M 7M 7M
capitalLeaseObligationsNonCurrent 0 85M 95M 98M 85M
treasuryStock -113 000 -146 000 -149 000 -21 000 0
additionalPaidInCapital 2 444M 2 123M 2 113M 2 108M 1 729M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND
reportedCurrency EUR EUR EUR EUR EUR EUR EUR EUR USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-07 2024-05-02 2024-02-07 2023-09-30 2023-06-30 2023-04-27 2022-09-30
acceptedDate 2025-11-12 16:15:33 2025-08-07 16:16:37 2025-02-12 16:15:38 2024-05-02 16:22:05 2024-02-07 16:05:50 2024-02-07 16:15:52 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-04-27 16:01:27 2023-02-16 16:31:10 2022-09-30 00:00:00 2022-03-02 16:20:10 2021-03-10 16:50:24
calendarYear 2025 2025 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -61M -39M -378M -109M -131M -481M -162M -121M -111M -583M -169M -384M -419M
depreciationAndAmortization 4M 4M 18M 4M 4M 19M 5M 5M 5M 18M 5M 15M 9M
deferredIncomeTax 4M 4M 5M 0 3M 0 645 000 -429 000 1M 5M -167 000 -367 000 -219 000
stockBasedCompensation 31M 30M 96M 26M 17M 67M 17M 20M 14M 64M 14M 67M 53M
changeInWorkingCapital 25M -44M -107M -24M -52M -96M -24M -35M -26M -12M 25M -48M -964 000
accountsReceivables -25M -48M -119M -11M -11M -33M -14M 0 -9608 -12M 0 -7M -2M
inventory 1M -10M -87M -19M -24M -78M -21M -17M -20M -55M -3M -75M 0
accountsPayables 0 0 0 9M -19M 0 4M 0 0 0 0 0 0
otherWorkingCapital 48M 14M 98M -3M 6M 15M 7M -17M -6M 54M 28M 34M 1M
otherNonCashItems 229 000 37M 61M 42M 49M 25M 39M -21M -30M 12M 27M -68M 86M
netCashProvidedByOperatingActivities 2M -7M -306M -61M -102M -467M -125M -153M -147M -496M -99M -418M -272M
investmentsInPropertyPlantAndEquipment -53 000 -4M -1M -342 000 -199 000 -2M -976 000 -444 000 -1M -14M -3M -24M -20M
acquisitionsNet 0 0 0 0 0 0 47 341 0 0 0 0 -10M 0
purchasesOfInvestments 0 0 0 0 0 0 -47 341 0 0 -214M -71M -226M -538M
salesMaturitiesOfInvestments 0 0 7M 0 7M 0 23M 47M 212M 281M 88M 150M 263M
otherInvestingActivites 0 0 950 000 7M 46 000 0 0 0
netCashUsedForInvestingActivites -53 000 -4M 608 000 7M 22M 47M 211M 14M
debtRepayment -7M -5M -3M -3M -3M -3M -3M -1M
commonStockIssued 0 0 263 703 21M 6M 0 0 0
commonStockRepurchased 0 0 0 0 0 -2M 0 0 0 -105M 1000 -22M 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 45M 12M 365 000 21M 140M 208 000 2M 1M
netCashUsedProvidedByFinancingActivities 39M 7M -2M 18M 143M -2M -702 000 -76 000
effectOfForexChangesOnCash 4M -19M 23M 2M 4M -6M 6M 1M -6M 36M 21M 39M -53M
netChangeInCash 45M -24M 167M -62M -72M -53M 47M -107M 57M -2M -64M -138M -14M
cashAtEndOfPeriod 539M 494M 560M 259M 320M 392M 441M 394M 501M 445M 608M 446M 585M
cashAtBeginningOfPeriod 494M 518M 392M 320M 392M 445M 394M 501M 445M 446M 672M 585M 598M
operatingCashFlow 2M -7M -306M -61M -102M -467M -125M -153M -147M -496M -99M -418M -272M
capitalExpenditure -53 000 -4M -1M -342 000 -199 000 -2M -976 000 -444 000 -1M -14M -3M -24M -22M
freeCashFlow 2M -12M -308M -62M -102M -470M -126M -154M -148M -510M -102M -442M -293M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-12 2024-02-07 2023-02-16 2022-03-02 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 950 000 289M 10M -530 000 3M
netCashProvidedByInvestingActivities 7M 286M 62M -111M -291M
netDebtIssuance 123M 126M 497M -6M -5M
longTermNetDebtIssuance 123M 126M 497M -6M -5M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 310M -2M -105M 346M 581M
netCommonStockIssuance 310M -2M -105M 346M 581M
commonStockIssuance 310M 0 0 368M 581M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 11M 10M 5M 12M 27M
netCashProvidedByFinancingActivities 444M 134M 397M 351M 603M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 16M 0 0 0

Earning call transcript

2025 q3
2025-11-12 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-12 ET (fiscal 2024 q4)
2024 q3
2024-11-14 ET (fiscal 2024 q3)
2024 q2
2024-09-03 ET (fiscal 2024 q2)
2024 q1
2024-05-04 ET (fiscal 2024 q1)
2023 q4
2024-02-07 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-09-05 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-04 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-07 11:30 ET
Ascendis Pharma Reports First Quarter 2026 Financial Results
2026-05-06 20:01 ET
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
2026-04-30 20:01 ET
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
2026-04-21 20:31 ET
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
2026-04-20 ET
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
2026-04-08 ET
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
2026-04-08 ET
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
2026-04-06 ET
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
2026-03-17 ET
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
2026-03-16 ET
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
2026-03-02 ET
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
2026-02-27 ET
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
2026-02-11 21:01 ET
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
2026-02-04 ET
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
2026-01-09 ET
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
2026-01-08 ET
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
2026-01-05 ET
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-11-25 23:15 ET
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
2025-11-17 21:01 ET
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
2025-11-12 21:01 ET
Ascendis Pharma Reports Third Quarter 2025 Financial Results
2025-11-07 13:30 ET
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
2025-11-05 21:01 ET
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
2025-11-03 21:01 ET
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
2025-10-08 20:01 ET
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia
2025-09-02 ET
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025
2025-08-28 ET
Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference
2025-08-07 ET
Ascendis Pharma Reports Second Quarter 2025 Financial Results
2025-07-31 ET
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
2025-07-28 ET
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
2025-07-14 ET
New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life
2025-07-07 ET
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
2025-06-09 ET
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
2025-06-02 ET
FDA Accepts TransCon® CNP NDA for Priority Review
2025-05-29 ET
NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA
2025-05-13 ET
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
2025-05-12 ET
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
2025-05-05 ET
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025
2025-05-01 ET
Ascendis Pharma Reports First Quarter 2025 Financial Results
2025-04-24 ET
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
2025-03-31 ET
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
2025-02-24 ET
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
2025-02-20 ET
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
2025-02-12 ET
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
2025-02-12 ET
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-05 ET
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
2025-01-13 ET
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
2025-01-12 ET
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
2025-01-06 ET
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-19 ET
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
2024-12-16 ET
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
2024-12-12 ET
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
2024-12-09 ET
Orsini chosen by Ascendis to distribute treatment for rare endocrine disorder in the U.S.
2024-12-06 ET
Ascendis Pharma Selects PANTHERx® Rare for the Distribution of YORVIPATH® (palopegteriparatide)
2024-11-14 21:01 ET
Ascendis Pharma Reports Third Quarter 2024 Financial Results
2024-11-04 12:00 ET
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
2024-11-04 12:00 ET
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
2024-09-30 12:30 ET
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
2024-09-30 12:30 ET
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
2024-09-20 00:16 ET
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
2024-09-18 20:04 ET
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
2024-09-16 11:00 ET
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
2024-09-13 12:30 ET
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
2024-09-11 21:37 ET
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
2024-09-03 21:06 ET
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
2024-09-03 21:04 ET
Ascendis Pharma Reports Second Quarter 2024 Financial Results
2024-08-28 12:30 ET
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024
2024-08-12 13:00 ET
VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism
2024-08-12 11:00 ET
FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults
2024-06-24 20:45 ET
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
2024-06-04 20:01 ET
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-06-03 20:01 ET
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
2024-05-30 12:30 ET
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
2024-05-14 18:31 ET
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
2024-05-13 12:30 ET
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
2024-05-09 12:30 ET
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
2024-05-02 20:01 ET
Ascendis Pharma Reports First Quarter 2024 Financial Results
2024-04-25 20:46 ET
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
2024-04-24 12:30 ET
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
2024-03-04 13:30 ET
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
2024-02-07 21:01 ET
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
2024-02-07 13:30 ET
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-01-31 21:15 ET
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
2024-01-31 21:01 ET
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
2024-01-31 ET
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
2024-01-29 13:30 ET
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
2024-01-29 ET
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
2024-01-08 23:01 ET
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey
2024-01-08 13:20 ET
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries 
2024-01-07 22:45 ET
Ascendis Pharma Introduces Vision 2030
2024-01-07 19:00 ET
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
2023-12-28 21:15 ET
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 13:30 ET
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
2023-12-19 13:30 ET
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
2023-12-11 13:30 ET
FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism
2023-11-29 09:30 ET
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
2023-11-20 13:00 ET
Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism
2023-11-16 14:00 ET
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
2023-11-15 13:00 ET
Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA
2023-11-07 21:01 ET
Ascendis Pharma Reports Third Quarter 2023 Financial Results
2023-10-31 12:30 ET
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
2023-10-26 12:30 ET
Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023
2023-10-16 20:01 ET
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
2023-10-02 12:00 ET
Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting
2023-09-23 11:00 ET
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
2023-09-15 12:00 ET
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
2023-09-14 16:22 ET
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
2023-09-05 20:03 ET
Ascendis Pharma Reports Second Quarter 2023 Financial Results
2023-09-05 20:01 ET
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
2023-09-05 20:01 ET
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
2023-08-24 12:30 ET
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
2023-08-15 12:30 ET
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
2023-06-17 21:30 ET
One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
2023-06-13 11:00 ET
Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023
2023-06-07 12:30 ET
Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-05 21:30 ET
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
2023-05-31 12:30 ET
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates
2023-05-25 12:30 ET
Ascendis Pharma to Host Oncology Program Update on May 31
2023-05-13 23:00 ET
Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023
2023-05-03 20:15 ET
Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference
2023-05-01 11:00 ET
U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism
2023-04-27 20:01 ET
Ascendis Pharma Reports First Quarter 2023 Financial Results
2023-04-13 12:30 ET
Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27
2023-04-03 11:05 ET
Ascendis Pharma’s Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon™ IL-2 β/γ Accepted for Online Publication at ASCO 2023
2023-04-03 11:00 ET
Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH™ in Hypoparathyroidism
2023-03-10 13:00 ET
Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference
2023-02-16 21:01 ET
Ascendis Pharma Reports Full Year 2022 Results
2023-02-07 13:00 ET
Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
2023-01-08 22:00 ET
Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference
2023-01-04 13:00 ET
Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism
2023-01-03 13:00 ET
Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-05 13:00 ET
Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
2022-11-22 13:30 ET
Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
2022-11-17 07:18 ET
VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin
2022-11-14 12:00 ET
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism
2022-11-13 23:15 ET
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
2022-11-11 17:10 ET
Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022
2022-11-02 20:01 ET
Ascendis Pharma Reports Third Quarter 2022 Financial Results
2022-10-31 12:00 ET
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
2022-10-26 12:00 ET
Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2
2022-10-03 12:00 ET
Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors
2022-09-12 12:00 ET
New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma’s TransCon™ PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022
2022-09-01 12:00 ET
Ascendis Pharma A/S Announces Upcoming Investor Presentations in September
2022-08-31 12:27 ET
Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism
2022-08-10 20:01 ET
Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
2022-08-04 12:00 ET
Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10
2022-06-07 12:00 ET
Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022
2022-05-23 12:00 ET
Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
2022-05-23 12:00 ET
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
2022-05-11 20:01 ET
Ascendis Pharma A/S Reports First Quarter 2022 Financial Results
2022-05-09 12:00 ET
Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference
2022-05-04 20:05 ET
Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11
2022-05-01 11:00 ET
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May
2022-03-25 02:41 ET
Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering
2022-03-23 20:01 ET
Ascendis Pharma Announces Proposed Convertible Senior Notes Offering
2022-03-13 21:53 ET
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
2022-03-02 21:01 ET
Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update
2022-02-25 13:00 ET
Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2
2022-02-10 21:05 ET
Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-13 13:00 ET
Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency
2022-01-10 13:00 ET
Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P. Morgan Healthcare Conference
2022-01-04 13:00 ET
Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference
2021-12-14 13:00 ET
Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline
2021-12-07 22:41 ET
Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
2021-11-18 21:42 ET
Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism
2021-11-17 21:05 ET
Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
2021-11-15 13:00 ET
Ascendis Pharma A/S - Share Repurchase Program Update
2021-11-12 12:22 ET
Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency
2021-11-10 21:01 ET
Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
2021-11-09 13:00 ET
Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021
2021-11-08 13:00 ET
Ascendis Pharma A/S - Share Repurchase Program Update
2021-11-03 12:00 ET
Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10
2021-10-15 12:00 ET
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
2021-09-30 20:01 ET
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting
2021-09-29 20:01 ET
Ascendis Pharma A/S Announces Share Repurchase Program
2021-09-22 20:27 ET
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks
2021-09-07 21:09 ET
Ascendis Pharma A/S Announces Upcoming Investor Presentations
2021-09-07 20:59 ET
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program
2021-09-01 23:43 ET
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
2021-08-31 20:01 ET
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
2021-08-25 20:12 ET
Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results
2021-08-25 19:24 ET
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency
2021-08-17 20:17 ET
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25
2021-08-06 11:05 ET
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
2021-07-06 12:00 ET
Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update
2021-06-11 21:57 ET
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency
2021-06-03 18:00 ET
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
2021-05-28 11:05 ET
Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021
2021-05-27 20:01 ET
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
2021-05-17 20:05 ET
Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27
2021-05-12 20:28 ET
Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan
2021-05-10 21:17 ET
Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile
2021-05-06 20:05 ET
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences
2021-05-04 20:05 ET
Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference
2021-04-21 20:05 ET
Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences
2021-03-30 11:05 ET
Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum
2021-03-23 11:05 ET
Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021
2021-03-15 11:05 ET
Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference
2021-03-10 21:01 ET
Ascendis Pharma A/S Reports Full Year 2020 Financial Results
2021-03-10 12:05 ET
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
2021-03-04 21:05 ET
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
2021-02-26 12:05 ET
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
2021-02-18 21:05 ET
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
2021-01-11 00:04 ET
Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference
2021-01-09 03:06 ET
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
2021-01-09 00:39 ET
Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
2021-01-07 10:45 ET
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
2021-01-04 12:05 ET
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
2020-12-30 21:05 ET
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
2020-12-14 21:05 ET
Ascendis Pharma A/S Announces Planned Board Transition
2020-11-25 12:05 ET
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
2020-11-11 22:30 ET
Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20
2020-11-11 21:01 ET
Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results
2020-11-03 12:05 ET
Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases
2020-11-02 21:05 ET
Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11
2020-10-23 12:05 ET
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe
2020-10-21 21:51 ET
Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences
2020-09-28 23:00 ET
Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon PTH in Adult Hypoparathyroidism
2020-09-23 20:05 ET
Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan
2020-09-15 21:45 ET
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2020
2020-09-11 11:05 ET
Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference
2020-09-10 11:05 ET
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting
2020-09-08 20:44 ET
Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency
2020-09-04 12:30 ET
Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)
2020-09-04 11:05 ET
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at 22nd European Congress of Endocrinology
2020-09-02 20:05 ET
Ascendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare Conference
2020-08-27 20:01 ET
Ascendis Pharma A/S Reports Second Quarter 2020 Financial Results and Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial
2020-08-13 20:01 ET
Ascendis Pharma A/S Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 27
2020-08-12 11:05 ET
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe
2020-08-04 12:30 ET
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
2020-07-08 02:11 ET
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
2020-07-06 16:58 ET
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
2020-07-06 13:24 ET
Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan
2020-06-26 12:29 ET
Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency
2020-06-22 12:30 ET
Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020
2020-06-08 12:15 ET
Ascendis Pharma A/S Announces Participation in ENDO Online 2020
2020-05-19 20:01 ET
Ascendis Pharma A/S Reports First Quarter 2020 Financial Results
2020-05-11 12:30 ET
Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer
2020-05-07 20:01 ET
Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19
2020-04-19 20:00 ET
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism
2020-04-15 20:58 ET
Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States
2020-04-01 20:01 ET
Ascendis Pharma A/S Reports Full-Year 2019 Financial Results
2020-03-25 20:01 ET
Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1
2020-02-12 21:01 ET
Ascendis Pharma A/S Announces Upcoming Investor Presentation in February
2020-01-13 00:45 ET
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference
2020-01-09 21:00 ET
Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference
2019-11-18 21:01 ET
Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results
2019-11-14 21:01 ET
Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States
2019-11-08 21:02 ET
Ascendis Pharma A/S Announces Upcoming Investor Presentation in November
2019-11-06 21:02 ET
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019
2019-11-04 23:30 ET
Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18
2019-10-21 20:04 ET
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe
2019-09-26 12:25 ET
Ascendis Pharma A/S Announces Upcoming Investor Presentation in October
2019-09-12 20:20 ET
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting
2019-04-03 20:01 ET
Ascendis Pharma A/S Reports Full Year 2018 Financial Results
2019-03-27 21:00 ET
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3
2019-03-25 18:00 ET
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

SEC forms

Show financial reports only

SEC form 6
2026-05-13 20:05 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-05-13 20:05 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-05-07 11:50 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-05-07 11:50 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-05-07 11:45 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-04-21 21:16 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-04-21 13:22 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-04-20 12:02 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-04-15 22:09 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-04-15 22:09 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-04-08 20:02 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-04-08 20:01 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-04-07 10:01 ET
Ascendis Pharma published news for 2026 q1
SEC form 6
2026-03-30 21:29 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-03-30 21:29 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-03-24 20:05 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-03-17 20:05 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-03-16 20:05 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-03-11 20:06 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-03-11 20:06 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-03-02 11:05 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-02-23 21:05 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-02-23 21:05 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-02-23 21:05 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-02-23 21:05 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-02-11 16:50 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-02-11 16:50 ET
Ascendis Pharma reported for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 20
2026-02-11 16:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-02-11 06:01 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-02-11 06:01 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-01-14 21:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-01-14 21:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-01-12 11:04 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-01-08 18:26 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2025-12-30 21:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-12-30 21:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-12-10 21:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-12-10 21:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-26 02:47 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-12 16:39 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-12 16:39 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-12 16:15 ET
Ascendis Pharma reported for 2025 q3
SEC form 6
2025-11-12 16:05 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-12 16:05 ET
Ascendis Pharma reported for 2025 q3
SEC form 6
2025-10-22 21:00 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-10-15 20:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-10-15 20:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-10-08 20:13 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-09-30 20:02 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-09-30 20:02 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-09-10 20:04 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-09-10 20:04 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-08-13 20:01 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-08-13 20:01 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-08-07 20:16 ET
Ascendis Pharma reported for 2025 q2
SEC form 6
2025-08-07 20:05 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-08-07 20:05 ET
Ascendis Pharma reported for 2025 q2
SEC form 6
2025-07-28 11:15 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-07-09 20:01 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-07-09 20:01 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-06-27 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-27 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-11 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-11 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-09 20:03 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-09 20:03 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-09 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-02 12:06 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-28 20:03 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-28 20:03 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-14 20:00 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-14 20:00 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-01 20:46 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-01 20:46 ET
Ascendis Pharma reported for 2025 q1
SEC form 6
2025-05-01 20:15 ET
Ascendis Pharma reported for 2025 q1
SEC form 6
2025-04-29 20:05 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-29 20:05 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-29 20:05 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-29 20:05 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-09 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-09 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-03-31 20:01 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-28 20:01 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-28 20:01 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-20 20:17 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-12 20:48 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-12 20:48 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 16:12 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 16:07 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 16:07 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 15:24 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 15:24 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2024-11-14 16:19 ET
Ascendis Pharma published news for 2024 q3
SEC form 6
2024-11-14 16:19 ET
Ascendis Pharma reported for 2024 q3
SEC form 6
2024-11-14 00:00 ET
Ascendis Pharma reported for 2024 q3
SEC form 6
2024-11-13 16:02 ET
Ascendis Pharma published news for 2024 q3
SEC form 6
2024-11-13 16:02 ET
Ascendis Pharma published news for 2024 q3
SEC form 6
2024-11-04 07:05 ET
Ascendis Pharma published news for 2024 q3
SEC form 6
2024-09-03 17:14 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-09-03 17:11 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-09-03 17:11 ET
Ascendis Pharma reported for 2024 q2
SEC form 6
2024-09-03 00:00 ET
Ascendis Pharma reported for 2024 q2
SEC form 6
2024-08-14 16:02 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-08-14 16:02 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-08-12 07:05 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-07-10 16:01 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-07-10 16:01 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-06-28 06:07 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-06-28 06:07 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-06-12 16:01 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-06-12 16:01 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:29 ET
Ascendis Pharma reported for 2024 q1
SEC form 6
2024-05-02 16:22 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:22 ET
Ascendis Pharma reported for 2024 q1
SEC form 6
2024-05-02 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-04-24 09:16 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-04-10 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-04-10 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-03-27 16:01 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-03-27 16:01 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-03-14 16:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-03-14 16:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-29 16:21 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-14 16:07 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-14 16:07 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-07 16:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-07 16:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-31 16:01 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-29 08:36 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-10 16:02 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-10 16:02 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-08 06:08 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-08 06:08 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-08 06:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-02 06:08 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-02 06:08 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2023-11-07 16:03 ET
Ascendis Pharma published news for 2023 q3
SEC form 6
2023-11-07 16:01 ET
Ascendis Pharma published news for 2023 q3
SEC form 6
2023-10-11 16:01 ET
Ascendis Pharma published news for 2023 q3
SEC form 6
2023-09-29 16:01 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-14 12:42 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-13 16:01 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-05 16:15 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-05 16:14 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-05 16:09 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-05 16:05 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-08-09 16:01 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-07-12 16:02 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-06-30 16:06 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-20 08:05 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-20 08:00 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-14 16:01 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-05 17:32 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-01 16:03 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-05-31 12:01 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-05-31 08:35 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-04-27 00:00 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-04-03 08:02 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-03-30 16:03 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-03-15 16:02 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-03-13 07:15 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-03-01 16:03 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-02-16 16:31 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-02-16 16:01 ET
Ascendis Pharma published news for 2022 q4
SEC form 20
2023-02-16 00:00 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-02-15 16:01 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-01-11 16:02 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-01-09 08:03 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-01-09 08:00 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-01-03 16:02 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2022-12-14 16:03 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-12-05 08:06 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-14 08:05 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-14 08:01 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-14 07:06 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-09 16:04 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-02 16:05 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-02 00:00 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-10-31 08:11 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-10-12 16:02 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-10-03 09:00 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-09-30 16:02 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-09-14 16:06 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-09-12 16:06 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-31 16:05 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-12 16:01 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-10 16:18 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-10 16:08 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-10 00:00 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-07-13 17:04 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-06-30 16:01 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-06-15 16:03 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-06-02 16:01 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-23 08:30 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-11 16:14 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-11 16:01 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-11 00:00 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-02 06:25 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-02 06:19 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-04-13 16:12 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-03-31 17:53 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-29 17:01 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-14 08:01 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-14 06:07 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-09 16:33 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-02 16:20 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-02 16:13 ET
Ascendis Pharma published news for 2021 q4
SEC form 20
2022-03-02 00:00 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-02-09 14:03 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-13 08:12 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-12 15:37 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-10 08:24 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-10 08:20 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-04 13:42 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2021-12-15 18:03 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-12-15 11:45 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-12-13 16:53 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-18 16:57 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-18 16:01 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-12 13:04 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-10 17:23 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-10 16:11 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-10 00:00 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-10-21 06:06 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-10-15 08:30 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-10-13 21:45 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-10-01 16:01 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-09-22 17:10 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-09-15 21:45 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-09-07 17:12 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-09-07 16:55 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-08-27 00:00 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-08-25 21:51 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-08-25 21:49 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-08-12 16:02 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-07-15 16:02 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-07-06 08:31 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-07-01 16:05 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-06-14 09:00 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-06-11 17:31 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-06-10 16:02 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-28 17:17 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-27 00:00 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-12 21:45 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-12 16:36 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-11 06:08 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-11 06:01 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-04-30 17:23 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-04-14 21:07 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-04-01 17:10 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-03-10 16:50 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-03-10 16:21 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-03-09 17:27 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-02-10 19:49 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-01-13 16:08 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-01-11 06:17 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-01-11 06:09 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2020-12-31 06:09 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-12-30 16:06 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-12-14 16:30 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-12-11 17:13 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-11-20 12:01 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-11-12 06:13 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-11-12 06:11 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-10-23 09:47 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-10-15 18:11 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-10-05 16:04 ET
Ascendis Pharma published news for 2020 q3